|
|
 |
 |
| |
 Printable version |
Treatment of chronic hepatitis B in HIV co-infected patients |
Hépato-Gastro. Volume 14, Number 5, 53-7, Numéro spécial : Prise en charge de l’hépatite chronique B en 2007, Mini-revue
|
 Résumé
Article gratuit
|
Author(s) : Yves Benhamou |
Summary : Because of complex interactions between HIV, HBV, immune system and antiretrovirals, treatment of HBV infection in HIV population should consider both viruses. In co-infected patients with no indication of antiretrovirals, drugs with dual activity against HBV and HIV are not recommended to avoid development of HIV resistance (lamivudine, emtricitabine, entecavir, tenofovir disoproxil fumarate). Adefovir dipivoxil (ADV) or pegylated interferon may be used. Telbivudine may have a role in combination with ADV in this situation. In patients with an indication of antiretroviral therapy, regimens should include tenofovir (TDF) in association with lamivudine (LAM) or emtricitabine. In patients who had developed HBV LAM (or emtricitabine) resistance addition of TDF to antiretroviral regimen including maintenance of LAM or emtricitabine is the preferred choice. |
Keywords : HIV, HBV, lamivudine, emtricitabine, entecavir, telbivudine, tenofovir disoproxil fumarate, adefovir dipivoxil |
|
